洋地黄毒素
癌症
药理学
心苷
癌细胞
心脏毒性
药品
细胞凋亡
医学
布法林
天然产物
化学
癌症研究
内科学
化疗
心力衰竭
生物化学
哇巴因
地高辛
有机化学
钠
标识
DOI:10.1517/14728222.11.8.1043
摘要
Accumulating preclinical and clinical data suggest that the cardiac drug digitoxin might be used in cancer therapy. Recent reports have shown that digitoxin can inhibit the growth and induce apoptosis in cancer cells at concentrations commonly found in the plasma of cardiac patients treated with this drug. Several mechanisms have been associated with the anticancer activity of digitoxin, yet at present it is unknown why malignant cells are more susceptible to this cardiac glycoside than non-malignant cells. This report analyses the possible anticancer mechanisms of digitoxin and proposes that the inhibition of glycolysis may be a key mechanism by which this natural product selectively targets cancer cells. Finally, whether or not there is enough evidence to support the clinical evaluation of digitoxin in patients with cancer is discussed.
科研通智能强力驱动
Strongly Powered by AbleSci AI